Current Report Filing (8-k)
February 26 2018 - 7:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
February 23, 2018
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Delaware
|
|
001-36457
|
|
90-0031917
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
10025
Investment Drive, Suite 250, Knoxville, TN 37932
(Address
of Principal Executive Offices)
(866)
594-5999
(Registrant’s
Telephone Number, Including Area Code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01.
|
Entry
Into a Material Definitive Agreement.
|
On
February 23, 2018, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a secured convertible promissory note
in favor of Timothy C. Scott, Ph.D. (“Scott”), the Company’s President, in the original principal amount of
$250,000 (“Scott’s PRH Note”). The terms of Scott’s PRH Note are substantially identical to the terms
of the notes the Company issued to a group of the Company’s stockholders (the “PRH Group”) pursuant to that
certain Definitive Financing Commitment Term Sheet by and between the Company and the PRH Group, effective as of March 19, 2017
(individually a “PRH Note” and collectively, the “PRH Notes”). The terms of the PRH Notes were disclosed
in the Company's Current Report on Form 8-K filed by the Company with the Commission on April 4, 2017. The foregoing description
of Scott’s PRH Note does not purport to be complete and is qualified in its entirety by reference to Scott’s PRH Note,
a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item
2.03.
|
Creation
of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
|
The
information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
February 26, 2018
|
|
|
|
|
|
|
PROVECTUS BIOPHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
John Glass
|
|
|
John
Glass
|
|
|
Interim
Chief Financial Officer
|
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024